ARBITER 6-HALTS: Niacin superior to ezetimibe
Links shared publicly online about this topic.
- 1,598total visits
ARBITER 6-HALTS: Niacin superior to ezetimibe
View full resource at endocrinetoday.com
Tags: Heart, Cholesterol Medication, Vitamin, American Heart Association, Zetia, Niaspan
Most Recently Shared on November 16, 2009 at 3:22 pm By:
ARBITER 6-HALTS: Niacin superior to ezetimibe http://ow.ly/CKTK #AHA09
Full ARBITER 6-HALTS results for niacin/ezetimibe study
theheart.org — “The final results of ARBITER 6-HALTS, which include an additional 107 patients who completed the closeout assessment after a mean of seven months of treatment, are line with the preliminary results showing that niacin added to statin therapy resulted in a significant regression of carotid IMT, whereas treatment with ezetimibe did not.” View full resource at theheart.org
Most Recently Shared on April 15, 2010 at 7:46 am By:
James Rudd Physician, Doctor, Internist, and Cardiologist
ARBITER 6-HALTS: Final results from complete study population published http://j.mp/9vV9CR
Full ARBITER 6-HALTS results for niacin/ezetimibe study
theheart.org — “The final results of ARBITER 6-HALTS, which include an additional 107 patients who completed the closeout assessment after a mean of seven months of treatment, are line with the preliminary results showing that niacin added to statin therapy resulted in a significant regression of carotid IMT, whereas treatment with ezetimibe did not.” View full resource at theheart.org
Most Recently Shared on April 14, 2010 at 9:25 pm By:
ARBITER 6-HALTS: Final results from complete study population published: The final results of ARBITER 6-HALT... http://bit.ly/9R2x2l #ACC10
70% Of Physicians on Sermo State They Would Increase Their Use of Niacin Based on the ARBITER 6-HALTS Trial | Business Wire
businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sermo (http://www.sermo.com), the world's largest online physician's community, today announced the results of a new report indicating that 70% of 350 US physician respondents would increase their use of niacin based on results from the ARBITER 6-HALTS trial. The head-to-head trial demonstrated the superiority of extended-release niacin (Abbott) over ezetimibe (Merck’s Zetia) when combined with statin therapy. This data is part of Sermo’s ne” View full resource at businesswire.com
Most Recently Shared on December 2, 2009 at 3:03 pm By:
Fabio Gratton Health Executive and Health Social Media
Sermo publishes first report of new "FirstLine" series, revealing 70% of HCPs wld increase Niacin use based on trial data: http://tr.im/GpSJ
70% Of Physicians on Sermo State They Would Increase Their Use of Niacin Based on the ARBITER 6-HALTS Trial
businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sermo (http://www.sermo.com), the world's largest online physician's community, today announced the results of a new report indicating that 70% of 350 US physician respondents would increase their use of niacin based on results from the ARBITER 6-HALTS trial. The head-to-head trial demonstrated the superiority of extended-release niacin (Abbott) over ezetimibe (Merck’s Zetia) when combined with statin therapy. This data is part of Sermo’s ne” View full resource at businesswire.com
Most Recently Shared on December 1, 2009 at 1:59 pm By:
Sermo Team Health Social Media
"70% Of Physicians on Sermo State They Would Increase Their Use of Niacin Based on the ARBITER 6-HALTS Trial" http://tinyurl.com/ygvbge3
The effects of ezetimibe vs. niacin on measures of mean carotid IMT in HALTS trial
endocrinetoday.com — “American Heart Association Scientific Sessions 2009 In today’s online issue of the New England Journal of Medicine, Taylor et al described” View full resource at endocrinetoday.com
Most Recently Shared on November 16, 2009 at 3:51 pm By:
In-depth analysis of the ARBITER 6-HALTS trial http://ow.ly/CL0e #AHA09
ARBITER 6-HALTS
theheart.org — “Extended-release niacin is superior to ezetimibe in its effect on carotid intima-media thickness. While experts say the trial tells clinicians little about ezetimibe, it is a big win for niacin given the substantial regression of atherosclerosis observed at eight and 14 months.” View full resource at theheart.org
Most Recently Shared on November 15, 2009 at 11:32 pm By:
ARBITER 6-HALTS: HDL raising with niacin superior to ezetimibe http://bit.ly/2SPFgp #SS09 #aha09
Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on July 13, 2009 at 1:28 pm By:
M Auron MD Physician, Doctor, Pediatrician, and Internist
Esetimibe vs niacin trial stopped, but not for safety reasons -will the cheap niacin be superior??? - http://bit.ly/xeRkx
HALTS halted
theheart.org — “UPDATEDWITH COMMENTARY // The study compared the effects of ezetimibe vs extended-release niacin on carotid intima-media thickness and was stopped by the steering committee based on results of a” View full resource at theheart.org
Most Recently Shared on July 9, 2009 at 10:06 pm By:
heartwire: ARBITER-6 HALTS stopped early: Safety not an issue, but little else known http://bit.ly/4K7EA
Advertisement
